American Association for Cancer Research to Host Lung Cancer Conference
January 6, 2010
CORONADO, Calif. — Promising results from Phase II clinical trials and important biological advances in diagnosis and prognosis were presented here, at the conference on Molecular Origins of Lung Cancer from Jan. 11-14, 2010. This conference is jointly sponsored by the AACR and the International Association for the Study of Lung Cancer.
Lung cancer kills more people than breast, prostate, kidney, colon, liver and skin cancers combined, but emerging scientific exploration offers some reason for hope in the fight against lung cancer, according to Roy Herbst, M.D., Ph.D., chief of the section of thoracic medical oncology at the University of Texas M. D. Anderson Cancer Center.
“Since the discovery of the epidermal growth factor receptor gene mutation almost five years ago, lung cancer has truly become a field where personalized molecular therapy is a part of day-to-day treatment,” said Herbst, who is also a chairperson of this conference. “We are now trying to uncover mechanisms of resistance and other targeted pathways that can be used to further our progress against this deadly disease.”
In an effort to assist the news media in its coverage of this conference, Herbst hosted a media roundtable on “Personalized Therapy for Lung Cancer: Are We Ready for Prime Time?” on Jan. 12, 2010, at 1:00 p.m. PT, in the Sovereign Room of the Loews Coronado Bay Resort in Coronado, Calif. (recording available below)
Herbst was joined by the following panelists, who present exciting new data and analysis from the conference on this emerging field:
• Tyler Jacks, Ph.D., president of the American Association for Cancer Research and director of the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology;
• Paul A. Bunn Jr., M.D., professor of medicine and James Dudley chair in cancer research at the University of Colorado, Denver;
• David Carbone, M.D., Ph.D., Harold L. Moses chair in cancer research and director of the Specialized Program of Research Excellence in Lung Cancer at Vanderbilt-Ingram Cancer Center; and
• Matthew Meyerson, M.D., Ph.D., professor of pathology at Dana-Farber Cancer Institute and Broad Institute at the Massachusetts Institute of Technology and Harvard University.
Listen to a recording of the teleconference:
* the mp3 of the teleconference (36.5 MB, 53 minutes and 10 seconds)
*On a PC, right mouse click on the "Download" link and select "Save link as..." in Firefox or "Save Target as..." in Internet Explorer.
Subscribe to the AACR RSS news feed
# # #
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world’s oldest and largest professional organization dedicated to advancing cancer research. The membership includes 30,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and nearly 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowship and career development awards. The AACR Annual Meeting attracts more than 16,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. The AACR publishes six major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists. CR provides a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship and advocacy.
In Coronado, Jan. 11-14: